Literature DB >> 17428173

Medical treatment of pancreatic cancer.

J-Matthias Löhr1.   

Abstract

Pancreatic carcinoma is a devastating disease with the worst prognosis of all solid tumors; the only cure is surgery. The vast majority of patients are inoperable at the time of diagnosis and require palliative treatment. With a median survival time oscillating around 6 months, indicating an almost complete resistance to conventional cytotoxic and radiation therapy, there is ample room for improvement. Therefore, pancreatic carcinoma has been used to trial many new substances and novel concepts. All aspects of palliative antitumor treatment will be presented in detail and discussed. Finally, some outlooks are given into the future of pancreatic cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428173     DOI: 10.1586/14737140.7.4.533

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

1.  An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Authors:  Georg Feldmann; Volker Fendrich; Karen McGovern; Djahida Bedja; Savita Bisht; Hector Alvarez; Jan-Bart M Koorstra; Nils Habbe; Collins Karikari; Michael Mullendore; Kathleen L Gabrielson; Rajni Sharma; William Matsui; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

2.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

Review 3.  Hedgehog signalling pathway: carcinogenesis and targeted therapy.

Authors:  Abdolali Ebrahimi; Leila Larijani; Afshin Moradi; Mohamad Reza Ebrahimi
Journal:  Iran J Cancer Prev       Date:  2013

4.  Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.

Authors:  Ting Zhao; Bijun Qiu; Senhao Zhou; Guoping Ding; Liping Cao; Zhengrong Wu
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.